Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
22 Mai 2024 - 2:00PM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company
developing innovative therapeutics targeting serious viral
diseases, today announced that the company will present data from
its herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline
programs at upcoming medical congresses. Assembly Bio’s abstracts
for ABI-5366 and ABI-1179 have been accepted for one oral and two
poster presentations at the International Herpesvirus Workshop,
taking place in Portland, Ore., July 13-17, 2024. An abstract for
ABI-6250 has been accepted for poster presentation at the European
Association for the Study of the Liver (EASL) Congress™ 2024 taking
place in Milan, Italy, June 5-8, 2024.
International Herpesvirus Workshop 2024At the
International Herpesvirus Workshop, Assembly Bio will present data
describing the preclinical profile of ABI-5366, a long-acting
helicase-primase inhibitor candidate in development for the
treatment of recurrent genital herpes. Additionally, the company
will present data highlighting the preclinical characterization of
ABI-1179, a structurally distinct long-acting helicase-primase
inhibitor candidate, which was licensed from Gilead Sciences, Inc.
(Gilead) under the collaboration between Assembly Bio and
Gilead.
“We’re excited to present data from both of these potent,
long-acting HSV helicase-primase inhibitors at the International
Herpesvirus Workshop,” said William Delaney, PhD, chief scientific
officer of Assembly Bio. “Improved therapeutic options are urgently
needed for people living with recurrent genital herpes, as the
current standard of care is only partially effective in controlling
recurrences. Our HSV program employs a highly innovative approach,
with candidates designed from the start for long-acting
administration and targeting the viral helicase-primase complex, a
different viral target than the standard of care. We look forward
to an important year for the program, as we remain on track to
begin dosing in a Phase 1a/1b study for ABI-5366 by mid-year and
anticipate bringing ABI-1179 into the clinic by end of year.”
Details of the presentations are as follows:
ABI-5366:
- Poster Presentation: The Helicase-Primase
Inhibitor ABI-5366 is a Novel, Potent, Long-Acting Inhibitor for
the Treatment of Recurrent Genital
HerpesPresenter: Ran Yan, PhD, Assembly
BioPoster Session Date and Time: Not Yet
Available
ABI-1179:
- Oral and Poster Presentation: Preclinical
Characterization of ABI-1179, a Potent Helicase-Primase Inhibitor
for the Treatment of Recurrent Genital
HerpesPresenter: Heidi Contreras, PhD, Assembly
BioOral Presentation Date and Time: July 16, 2024,
at 11:00 AM PDTPoster Session Date and Time: Not
Yet Available
EASL Congress™ 2024At EASL, Assembly Bio will
present preclinical profiling of ABI-6250, the company’s novel,
small molecule orally-bioavailable entry inhibitor candidate for
the treatment of chronic HDV.
“The preclinical findings we are presenting for ABI-6250
underscore the potential of this candidate to offer improved
treatment options to individuals living with chronic HDV,” said
Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio.
“Chronic HDV infection is the most serious form of viral hepatitis,
progressing to cirrhosis in the majority of cases within 10 years.
Unfortunately, the standard of care is currently only available in
Europe and requires daily injections, highlighting the potential we
see for a once-daily oral therapeutic option. We look forward to
moving ABI-6250 into the clinic, anticipated by the end of this
year.”
Details of the presentation are as follows:
ABI-6250:
- Poster WED-377: Preclinical profiling of
ABI-6250, a novel orally bioavailable small-molecule therapeutic
candidate for the treatment of chronic hepatitis
DPresenter: Marc P. Windisch, PhD, Assembly
BioSession: Viral Hepatitis B and D: New
therapies, unapproved therapies or strategiesDate and
Time: June 5, 2024, 8:30 AM-6:00 PM
The investigational product candidates referenced here have not
been approved anywhere globally, and their safety and efficacy have
not been established.
About Assembly BiosciencesAssembly
Biosciences is a biotechnology company dedicated to the development
of innovative small-molecule therapeutics designed to change the
path of serious viral diseases and improve the lives of patients
worldwide. Led by an accomplished team of leaders in virologic drug
development, Assembly Bio is committed to improving outcomes for
patients struggling with the serious, chronic impacts of
herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus
(HDV) infections. For more information, visit assemblybio.com.
Forward-Looking StatementsThe information in
this press release contains forward-looking statements that are
subject to certain risks and uncertainties that could cause actual
results to materially differ. These risks and uncertainties
include: Assembly Bio’s ability to realize the potential benefits
of its collaboration with Gilead Sciences, Inc., including all
financial aspects of the collaboration and equity investments;
Assembly Bio’s ability to initiate and complete clinical studies
involving its therapeutic product candidates, including studies
contemplated by Assembly Bio’s collaboration with Gilead, in the
currently anticipated timeframes or at all; safety and efficacy
data from clinical or nonclinical studies may not warrant further
development of Assembly Bio’s product candidates; clinical and
nonclinical data presented at conferences may not differentiate
Assembly Bio’s product candidates from other companies’ candidates;
results of nonclinical studies may not be representative of disease
behavior in a clinical setting and may not be predictive of the
outcomes of clinical studies; and other risks identified from time
to time in Assembly Bio’s reports filed with the U.S. Securities
and Exchange Commission (the SEC). You are urged to consider
statements that include the words may, will, would, could, should,
might, believes, hopes, estimates, projects, potential, expects,
plans, anticipates, intends, continues, forecast, designed, goal or
the negative of those words or other comparable words to be
uncertain and forward-looking. Assembly Bio intends such
forward-looking statements to be covered by the safe harbor
provisions contained in Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. More information about Assembly Bio’s risks and
uncertainties are more fully detailed under the heading “Risk
Factors” in Assembly Bio’s filings with the SEC, including its most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and Current Reports on Form 8-K. Except as required by law,
Assembly Bio assumes no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
ContactsInvestor and
Corporate:Shannon RyanSVP, Investor Relations, Corporate
Affairs and Alliance Management(415)
738-2992sryan@assemblybio.com
Media:Sam Brown Inc. Hannah
Hurdle (805) 338-4752 ASMBMedia@sambrown.com
Assembly Biosciences (NASDAQ:ASMB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Assembly Biosciences (NASDAQ:ASMB)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024